Agreat deal of effort is underway in order .to identify those men with prostatecancer felicitous for active surveillance with greater precision than that afforded to us today. In the manuscript by Irshad et al. the au...Agreat deal of effort is underway in order .to identify those men with prostatecancer felicitous for active surveillance with greater precision than that afforded to us today. In the manuscript by Irshad et al. the authors evaluate a novel set of genes associated with senescence and aging as tools that can provide guidance regarding the indolent nature of an individual＇s prostate cancer with validation using both mRNA and protein analyses. While additional studies are required to understand the full impact of these findings, the innovative approach taken enhances our understanding of distinct phenotypes of prostate cancer.展开更多
Androgen deprivation therapy(ADT)is the mainstay for the treatment of advanced prostate cancer.Since the clinical evolution from surgical orchiectomy,we have typically used ADT and orchiectomy to be synonymous terms f...Androgen deprivation therapy(ADT)is the mainstay for the treatment of advanced prostate cancer.Since the clinical evolution from surgical orchiectomy,we have typically used ADT and orchiectomy to be synonymous terms for castration.The goal of this study is to determine if,in contemporary medical practice,surgical and chemical castration provide for similar levels of diminishment of total and free testosterone.Further,what approaches should be used to most accurately measure testosterone levels in men with advanced prostate cancer and what cutoff values,for example for total testosterone 50 ng dl-1 or 20 ng dl-1,should be utilized.Studies available in the literature have been analyzed and compiled to address these questions.Finally,evidence is provided that free testosterone,the biologically active component,should be utilized to provide clinically relevant state of castration.展开更多
Dear Editor, In the 1940s, Charles Huggins discovered that surgical castration produced remarkable palliative benefits for men with advanced prostate cancer, an effect we now understand to be mediated through deprivi...Dear Editor, In the 1940s, Charles Huggins discovered that surgical castration produced remarkable palliative benefits for men with advanced prostate cancer, an effect we now understand to be mediated through depriving the androgen receptor （AR） from its ligands （i.e, testicular-derived androgens）.展开更多
文摘Agreat deal of effort is underway in order .to identify those men with prostatecancer felicitous for active surveillance with greater precision than that afforded to us today. In the manuscript by Irshad et al. the authors evaluate a novel set of genes associated with senescence and aging as tools that can provide guidance regarding the indolent nature of an individual＇s prostate cancer with validation using both mRNA and protein analyses. While additional studies are required to understand the full impact of these findings, the innovative approach taken enhances our understanding of distinct phenotypes of prostate cancer.
文摘Androgen deprivation therapy(ADT)is the mainstay for the treatment of advanced prostate cancer.Since the clinical evolution from surgical orchiectomy,we have typically used ADT and orchiectomy to be synonymous terms for castration.The goal of this study is to determine if,in contemporary medical practice,surgical and chemical castration provide for similar levels of diminishment of total and free testosterone.Further,what approaches should be used to most accurately measure testosterone levels in men with advanced prostate cancer and what cutoff values,for example for total testosterone 50 ng dl-1 or 20 ng dl-1,should be utilized.Studies available in the literature have been analyzed and compiled to address these questions.Finally,evidence is provided that free testosterone,the biologically active component,should be utilized to provide clinically relevant state of castration.
文摘Dear Editor, In the 1940s, Charles Huggins discovered that surgical castration produced remarkable palliative benefits for men with advanced prostate cancer, an effect we now understand to be mediated through depriving the androgen receptor （AR） from its ligands （i.e, testicular-derived androgens）.
